vs

Side-by-side financial comparison of Inotiv, Inc. (NOTV) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.

Inotiv, Inc. is the larger business by last-quarter revenue ($120.9M vs $71.1M, roughly 1.7× RE/MAX Holdings, Inc.). RE/MAX Holdings, Inc. runs the higher net margin — 2.0% vs -23.5%, a 25.5% gap on every dollar of revenue. On growth, Inotiv, Inc. posted the faster year-over-year revenue change (0.8% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $-10.6M). Over the past eight quarters, Inotiv, Inc.'s revenue compounded faster (0.8% CAGR vs -4.7%).

Inotiv, Inc. is a contract research organization organized in Indiana and headquartered in Lafayette, Indiana. The company operates two core business units: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The CRS business unit offers drug development and environmental sciences services, including safety assessment, analytical, metabolism, CMC and regulatory consultancy for small molecule drug candidates, biotherapeutics, and biomedical devices. The RMS business u...

RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.

NOTV vs RMAX — Head-to-Head

Bigger by revenue
NOTV
NOTV
1.7× larger
NOTV
$120.9M
$71.1M
RMAX
Growing faster (revenue YoY)
NOTV
NOTV
+2.7% gap
NOTV
0.8%
-1.8%
RMAX
Higher net margin
RMAX
RMAX
25.5% more per $
RMAX
2.0%
-23.5%
NOTV
More free cash flow
RMAX
RMAX
$44.1M more FCF
RMAX
$33.5M
$-10.6M
NOTV
Faster 2-yr revenue CAGR
NOTV
NOTV
Annualised
NOTV
0.8%
-4.7%
RMAX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
NOTV
NOTV
RMAX
RMAX
Revenue
$120.9M
$71.1M
Net Profit
$-28.4M
$1.4M
Gross Margin
Operating Margin
-13.5%
13.1%
Net Margin
-23.5%
2.0%
Revenue YoY
0.8%
-1.8%
Net Profit YoY
-2.7%
-75.2%
EPS (diluted)
$-0.83

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NOTV
NOTV
RMAX
RMAX
Q4 25
$120.9M
$71.1M
Q3 25
$138.1M
$73.2M
Q2 25
$130.7M
$72.8M
Q1 25
$124.3M
$74.5M
Q4 24
$119.9M
$72.5M
Q3 24
$130.4M
$78.5M
Q2 24
$105.8M
$78.5M
Q1 24
$119.0M
$78.3M
Net Profit
NOTV
NOTV
RMAX
RMAX
Q4 25
$-28.4M
$1.4M
Q3 25
$-8.6M
$4.0M
Q2 25
$-17.6M
$4.7M
Q1 25
$-14.9M
$-2.0M
Q4 24
$-27.6M
$5.8M
Q3 24
$-18.9M
$966.0K
Q2 24
$-26.1M
$3.7M
Q1 24
$-48.1M
$-3.4M
Operating Margin
NOTV
NOTV
RMAX
RMAX
Q4 25
-13.5%
13.1%
Q3 25
-4.9%
25.0%
Q2 25
-4.3%
19.3%
Q1 25
-2.4%
7.2%
Q4 24
-12.9%
5.9%
Q3 24
-10.1%
19.4%
Q2 24
-19.6%
20.6%
Q1 24
-36.2%
5.8%
Net Margin
NOTV
NOTV
RMAX
RMAX
Q4 25
-23.5%
2.0%
Q3 25
-6.2%
5.4%
Q2 25
-13.5%
6.4%
Q1 25
-12.0%
-2.6%
Q4 24
-23.0%
8.0%
Q3 24
-14.5%
1.2%
Q2 24
-24.7%
4.7%
Q1 24
-40.4%
-4.3%
EPS (diluted)
NOTV
NOTV
RMAX
RMAX
Q4 25
$-0.83
Q3 25
$-0.14
Q2 25
$-0.51
Q1 25
$-0.44
Q4 24
$-1.02
Q3 24
$-0.73
Q2 24
$-1.00
Q1 24
$-1.86

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NOTV
NOTV
RMAX
RMAX
Cash + ST InvestmentsLiquidity on hand
$12.7M
$118.7M
Total DebtLower is stronger
$405.8M
$432.2M
Stockholders' EquityBook value
$109.0M
$452.4M
Total Assets
$734.3M
$582.5M
Debt / EquityLower = less leverage
3.72×
0.96×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NOTV
NOTV
RMAX
RMAX
Q4 25
$12.7M
$118.7M
Q3 25
$21.7M
$107.5M
Q2 25
$6.2M
$94.3M
Q1 25
$19.3M
$89.1M
Q4 24
$38.0M
$96.6M
Q3 24
$21.4M
$83.8M
Q2 24
$14.4M
$66.1M
Q1 24
$32.7M
$82.1M
Total Debt
NOTV
NOTV
RMAX
RMAX
Q4 25
$405.8M
$432.2M
Q3 25
$402.1M
$433.3M
Q2 25
$396.5M
$434.4M
Q1 25
$399.5M
$435.3M
Q4 24
$396.0M
$436.2M
Q3 24
$393.3M
$437.2M
Q2 24
$382.4M
$438.1M
Q1 24
$380.6M
$439.0M
Stockholders' Equity
NOTV
NOTV
RMAX
RMAX
Q4 25
$109.0M
$452.4M
Q3 25
$136.0M
$448.1M
Q2 25
$143.8M
$442.4M
Q1 25
$157.7M
$433.5M
Q4 24
$169.8M
$429.5M
Q3 24
$170.5M
$423.1M
Q2 24
$182.1M
$418.4M
Q1 24
$207.2M
$412.0M
Total Assets
NOTV
NOTV
RMAX
RMAX
Q4 25
$734.3M
$582.5M
Q3 25
$771.1M
$582.2M
Q2 25
$759.7M
$574.8M
Q1 25
$766.0M
$571.4M
Q4 24
$772.9M
$581.6M
Q3 24
$781.4M
$578.6M
Q2 24
$774.6M
$571.4M
Q1 24
$815.4M
$566.7M
Debt / Equity
NOTV
NOTV
RMAX
RMAX
Q4 25
3.72×
0.96×
Q3 25
2.96×
0.97×
Q2 25
2.76×
0.98×
Q1 25
2.53×
1.00×
Q4 24
2.33×
1.02×
Q3 24
2.31×
1.03×
Q2 24
2.10×
1.05×
Q1 24
1.84×
1.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NOTV
NOTV
RMAX
RMAX
Operating Cash FlowLast quarter
$-5.4M
$40.9M
Free Cash FlowOCF − Capex
$-10.6M
$33.5M
FCF MarginFCF / Revenue
-8.8%
47.1%
Capex IntensityCapex / Revenue
4.3%
10.4%
Cash ConversionOCF / Net Profit
28.39×
TTM Free Cash FlowTrailing 4 quarters
$-28.7M
$56.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NOTV
NOTV
RMAX
RMAX
Q4 25
$-5.4M
$40.9M
Q3 25
$14.3M
$17.7M
Q2 25
$-7.4M
$4.6M
Q1 25
$-12.8M
$5.7M
Q4 24
$-4.5M
$59.7M
Q3 24
$-2.4M
$17.6M
Q2 24
$-14.8M
$15.9M
Q1 24
$16.9M
$9.4M
Free Cash Flow
NOTV
NOTV
RMAX
RMAX
Q4 25
$-10.6M
$33.5M
Q3 25
$11.6M
$16.4M
Q2 25
$-11.5M
$2.9M
Q1 25
$-18.3M
$4.0M
Q4 24
$-9.0M
$53.0M
Q3 24
$-7.7M
$16.3M
Q2 24
$-19.2M
$14.0M
Q1 24
$9.9M
$6.8M
FCF Margin
NOTV
NOTV
RMAX
RMAX
Q4 25
-8.8%
47.1%
Q3 25
8.4%
22.4%
Q2 25
-8.8%
4.0%
Q1 25
-14.7%
5.3%
Q4 24
-7.5%
73.2%
Q3 24
-5.9%
20.8%
Q2 24
-18.2%
17.8%
Q1 24
8.3%
8.6%
Capex Intensity
NOTV
NOTV
RMAX
RMAX
Q4 25
4.3%
10.4%
Q3 25
1.9%
1.8%
Q2 25
3.1%
2.2%
Q1 25
4.4%
2.3%
Q4 24
3.7%
9.1%
Q3 24
4.1%
1.7%
Q2 24
4.2%
2.4%
Q1 24
5.9%
3.3%
Cash Conversion
NOTV
NOTV
RMAX
RMAX
Q4 25
28.39×
Q3 25
4.45×
Q2 25
0.97×
Q1 25
Q4 24
10.28×
Q3 24
18.22×
Q2 24
4.29×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NOTV
NOTV

Research Models And Services Segment$72.9M60%
Discovery And Safety Assessment Segment$48.0M40%

RMAX
RMAX

Franchising Segment$50.1M70%
Broker Fees$13.9M20%
Annual Dues$7.4M10%

Related Comparisons